FreeOx Biotech Formally Launches Seed Round to Fund Phase III Pivotal Trial
Summary
As reported in SCIENCE TRANSLATIONAL MEDICINE, Uric Acid was the only one of five interventional drug candidates for which data supported further clinical evaluation, as it demonstrated unprecedented efficacy compared to the others. In addition to the pharmaceutical grade Uric Acid active ingredient in Ox-01, FreeOx is building a pipeline based on a proprietary liposomal formulation technology that broadly expands opportunities in neurology.Stroke is the leading cause of disability worldwide, according to the American Stroke Association. While advances have been made with mechanical thrombectomy, significant unmet needs exist when 50 percent of Large Vessel Occlusion patients have insufficient restoration of their microcirculation and ensuing disabilities.For more information about FreeOx Biotech and its groundbreaking stroke treatment technology, please visit the companys website at https://freeoxbiotech.com/.FreeOx Biotech is a leading late-stage clinical-stage biopharmaceutical company dedicated to developing Cerebrovascular Protective Therapy, a new drug class for the emergency treatment of Acute Ischemic Stroke (AIS) patients. By focusing on restoring microcirculation homeostasis and enhancing penumbra reperfusion, FreeOx Biotech aims to revolutionize stroke care and improve patient outcomes. Founded by Dr. !ngel Chamorro, MD, a leading stroke neurologist and pioneer in the use of Uric Acid as an emergency treatment for AIS, FreeOx s novel adjunct drug has been shown to reperfuse the brain microcirculation.